Regulatory Science Network Netherlands (RSNN)

Advancing an efficient and effective regulatory system for medicines

RSNN’s mission is to advance an efficient and effective regulatory system that supports medicines development, marketing authorization, access, and appropriate use of medicines. RSNN shares and disseminates knowledge among all stakeholders and sets the agenda for further research.

RSNN sets the agenda for regulatory science research to advance an efficient and effective regulatory system for medicines.

Regulatory Science Network Netherlands (RSNN), founded in 2015, is a network of experts from industry, academia, government bodies, and the broader regulatory science field. RSNN offers a unique platform for stakeholders from different backgrounds to meet and discuss regulatory science as equal partners. Our mission is to advance an efficient and effective regulatory system that supports medicines development, marketing authorization, access, and appropriate use of medicines. RSNN shares and disseminates knowledge among all stakeholders and sets the agenda for further research.

 A variety of activities support our mission. These include a yearly RSNN workshop around a topic that deserves or attracts interest, and also scientific sessions during conferences such as FIGON Dutch Medicines Days. Alongside its meeting reports, the RSNN stimulates publication of relevant papers based on RSNN activities designed to stimulate national and international debate on regulatory science. Participants in the network receive news on developments in the field via our regular newsletters.

 The RSNN is an inclusive organization, with all activities open to anyone interested. Such inclusiveness helps us to set agendas for future research, and to act as a breeding ground for new research initiatives.

Receive updates about RSNN events and activities by subscribing to the RSNN newsletter on our website or follow us on LinkedIn. For suggestions and questions, emails can be sent to info@rsnn.nl.
Bert Leufkens (chair RSNN), UMCU; Just Weemers (vice-chair), Janssen Biologics